About HOOKIPA Pharma, Inc.

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

At the moment the company generates 13M USD in revenues.

On its last earning announcement, the company reported a loss of -1.37$ per share.

The book value per share is 4.95$

HOOKIPA Pharma, Inc. website


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
13M - -36M -266.20% -35M -1.37 - - 25M 4.95 -39M -1M -41M